Related Experiment Video
Updated: May 19, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international
Dieter Haffner1, Franz Schaefer
1Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. haffner.dieter@mh-hannover.de
Insights
Optimal treatment for pediatric chronic kidney disease mineral and bone disorder (CKD-MBD) is crucial. A parathyroid hormone (PTH) range of 100-200 pg/ml is suggested for children on peritoneal dialysis.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Mineral and Bone Metabolism
Background:
- Mineral and bone disorder (CKD-MBD) in pediatric chronic kidney disease (CKD) presents significant challenges.
- Therapeutic goals include preventing skeletal complications, ensuring normal growth, and maintaining cardiovascular health.
- Current pediatric guidelines for optimal parathyroid hormone (PTH) targets lack robust evidence and show considerable variation.
Purpose of the Study:
- To review the evidence for optimal PTH target ranges in pediatric CKD patients.
- To re-evaluate current guidelines using data from the International Pediatric Dialysis Network (IPPN) global registry.
- To propose a reasonable PTH target range for children with CKD-MBD undergoing chronic peritoneal dialysis (PD).
Main Methods:
- Analysis of clinical and biochemical data from the IPPN global registry, focusing on CKD-MBD in children on chronic PD.
- Comprehensive evaluation of CKD-MBD outcome measures within this patient cohort.
- Review of existing literature and current pediatric consensus guidelines.
Main Results:
- The IPPN registry provides valuable data on CKD-MBD in pediatric PD patients.
- Existing guidelines for PTH targets in pediatric CKD are based on limited evidence.
- A PTH target range of 1.7-3 times the upper limit of normal (100-200 pg/ml) is identified as reasonable.
Conclusions:
- The established PTH target range of 100-200 pg/ml is supported by the IPPN registry data for children on chronic PD.
- This evidence-based range can aid in managing pediatric CKD-MBD.
- Further research may refine targets, but this range offers a practical guideline.
Abstract:
The treatment of the mineral and bone disorder associated with chronic kidney disease (CKD-MBD) remains a major challenge in pediatric patients. The principal aims of therapeutic measures are not only to prevent the debilitating skeletal complications and to achieve normal growth but also to preserve long-term cardiovascular health. Serum parathyroid hormone (PTH) levels are used as a surrogate parameter of bone turnover. Whereas it is generally accepted that serum calcium and phosphate levels should be kept within the range for age, current pediatric consensus guidelines differ markedly with respect to the optimal PTH target range and operate on a limited evidence base. Recently, the International Pediatric Dialysis Network (IPPN) established a global registry collecting detailed clinical and biochemical information, including data relevant to CKD-MBD in children on chronic peritoneal dialysis (PD). This review highlights the current evidence basis regarding the optimal PTH target range in pediatric CKD patients, and re-assesses the current guidelines in view of the outcome data collected by the IPPN registry. Based on a comprehensive evaluation of CKD-MBD outcome measures in this global patient cohort, a PTH target range of 1.7-3 times the upper limit of normal (i.e. 100-200 pg/ml) appears reasonable in children undergoing chronic PD.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis I: Introduction and Procedure
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

